STAT+: Makers of rare disease drugs seek exemption from Trump’s price-cut pilots

WASHINGTON — Biotech companies are lobbying the Trump administration to exclude treatments for rare diseases from programs that lower brand drug prices in Medicare.

The Rare Disease Company Coalition met last week with the White House Office of Management and Budget to discuss two pilot programs that are part of President Trump’s plan to get drugmakers to lower prices in the United States to levels charged in other rich countries, a policy generally referred to as most-favored nation.

Continue to STAT+ to read the full story…